首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1532535

生物製药发酵系统市场 - 产品类型（上游 [生物反应器、生物过程分析仪]、下游 [色谱、过滤]）、应用（重组蛋白、抗生素、益生菌）、最终用户 - 全球预测（2024 - 2032）

Biopharmaceutical Fermentation Systems Market - Product Type (Upstream [Bioreactor, Bioprocess Analyzer], Downstream [Chromatography, Filtration]), Application (Recombinant Proteins, Antibiotics, Probiotics), End User - Global Forecast (2024 - 2032)

出版日期: 2024年05月22日 | 出版商:

Global Market Insights Inc. | 英文 123 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在生物技术产业扩张的推动下，2024年至2032年全球生物製药发酵系统市场的复合年增长率将超过6%。随着生技公司不断开发新的生物製剂和生物相似药，对高品质发酵系统的需求日益增加。在此背景下，2024 年 5 月，GE HealthCare 在格拉斯哥举行的 ESTRO 2024 上推出了 Revolution RT。这种人工智慧增强型 CT 解决方案提高了成像准确性并简化了工作流程，从而增强了个人化肿瘤护理。该公司推出了更新的 iRT 平台和 MIM 软体产品组合，以解决复杂的癌症诊断和治疗延迟问题。

生物製药发酵系统对于生产复杂的生物药物和实现可扩展、高效的製造流程至关重要。生物技术创新的激增和研发投资的增加扩大了对先进发酵技术的需求。这些因素得到了对个人化医疗和新颖治疗方法的日益关注的支持，从而有利于市场前景。

整个生物製药发酵系统市场根据产品类型、最终用户、应用和地区进行分类。

在对后製处理的关注的推动下，下游产品领域到 2032 年将实现显着的复合年增长率。高效的下游加工对于生物製药产品的纯化和配製、确保高品质至关重要。随着生物製药公司强调优化这些工艺，对先进发酵系统的需求不断增长。此外，下游产品要求的复杂性需要复杂的技术来满足多样化和具有挑战性的加工需求。生物製药研究的不断进步和药物开发活动的不断增加进一步推动了产品的采用。

由于重视开发有效的抗生素，到 2032 年，抗生素领域将在生物製药发酵系统市场中占据大量份额。随着抗生素抗药性的增加，迫切需要先进的发酵技术来生产具有增强功效的新型抗生素。生产需要精确且可扩展的发酵工艺，以确保抗生素品质和产量的一致性。此外，满足严格的监管标准和加快新抗生素上市时间的需求也增加了对复杂发酵系统的需求。

由于对医疗保健创新和生物技术的高度重视，欧洲生物製药发酵系统市场在 2024 年至 2032 年期间将录得可观的复合年增长率。欧洲是生物製药研究的领导者，拥有许多专注于先进疗法和个人化医疗的公司。这项承诺推动了对复杂发酵系统的需求，以支持高品质的药物生产。严格的产品安全监管标准、生物技术投资的增加以及对新疗法不断增长的需求加速了该地区的市场成长。

产业生态系统分析
产业影响力
- 成长动力
  - 生物製药需求不断成长
  - 不断增加开发新生物製药和生物相似药的投资
  - 增加生物製药产品的监管审批
  - 越来越多地采用一次性发酵罐
- 产业陷阱与挑战
  - 高初始资本投资要求
  - 与可萃取物和可浸出物相关的问题
成长潜力分析
监管环境
未来市场趋势
差距分析
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按产品类型，2021 - 2032

主要趋势
上游产品
- 生物反应器/发酵罐
- 生物过程分析仪
- 过程监控系统
- 其他上游产品
下游产品
- 过滤与分离
- 色谱法
- 耗材及配件
- 其他下游产品

第 6 章：市场估计与预测：按应用分类，2021 - 2032

主要趋势
重组蛋白
抗生素
益生菌
其他应用

第 7 章：市场估计与预测：按最终用户划分，2021 - 2032 年

主要趋势
生物製药公司
合约研究组织
学术研究机构
其他最终用户

第 8 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

Agilent Technologies, Inc.
Becton, Dickinson and Company
Bioengineering AG
Cellexus Limited
Danaher Corporation
Eppendorf AG
F. Hoffmann-La Roche Ltd.
GE HealthCare Technologies, Inc.
Getinge Group
Lonza Group AG
Merck KGaA
Nova Biomedicals
Sartorius Stedim Biotech
Thermo Fisher Scientific Inc.
ZETA

简介目录

Product Code: 9589

Global Biopharmaceutical Fermentation Systems Market will witness over 6% CAGR from 2024 to 2032, driven by the expansion of the biotechnology sector. As biotech companies continue developing new biologics and biosimilars, the need for high-quality fermentation systems intensifies. Against this backdrop, in May 2024, GE HealthCare launched Revolution RT at ESTRO 2024 in Glasgow. This AI-enhanced CT solution improves imaging accuracy and simplifies workflows, enhancing personalized oncology care. The company unveiled the updated iRT platform and MIM Software portfolio to address complex cancer diagnostics and treatment delays.

Biopharmaceutical fermentation systems are essential for producing complex biological drugs and achieving scalable, efficient manufacturing processes. The surge in biotech innovation and increased investment in R&D amplifies the demand for advanced fermentation technologies. These factors are supported by the growing focus on personalized medicine and novel therapeutic approaches, in turn favoring the market outlook.

The overall biopharmaceutical fermentation systems market is classified based on product type, end-user, application, and region.

The downstream products segment will register a notable CAGR through 2032, driven by a focus on post-production processing. Efficient downstream processing is crucial for purifying and formulating biopharmaceutical products, ensuring high quality. As biopharmaceutical companies emphasize optimizing these processes, the need for advanced fermentation systems grows. Additionally, the complexity of downstream product requirements necessitates sophisticated technologies that can handle diverse and challenging processing needs. The ongoing advancements in biopharmaceutical research and the increasing volume of drug development activities are further fueling the product adoption.

The antibiotics segment will garner a substantial biopharmaceutical fermentation systems market share by 2032, owing to the emphasis on developing effective antibiotics. As antibiotic resistance grows, there is a pressing demand for advanced fermentation technologies to produce novel antibiotics with enhanced efficacy. The manufacturing requires precise and scalable fermentation processes to ensure the consistent quality & yield of antibiotics. Additionally, the need to meet stringent regulatory standards and accelerate time-to-market for new antibiotics catapults the demand for sophisticated fermentation systems.

Europe biopharmaceutical fermentation systems market will record a considerable CAGR during 2024-2032, because of the strong emphasis on healthcare innovation and biotechnology. Europe is a leader in biopharmaceutical research, with numerous companies focusing on advanced therapies and personalized medicine. This commitment drives the need for sophisticated fermentation systems to support high-quality drug production. Strict regulatory standards for product safety, the increasing investment in biotechnology, and the growing demand for new treatments accelerate the market growth in the region.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing demand for biopharmaceuticals
  - 3.2.1.2 Growing investments for developing new biopharmaceuticals and biosimilars
  - 3.2.1.3 Increasing regulatory approvals for biopharmaceutical products
  - 3.2.1.4 Growing adoption of single use fermenters
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Requirements for high initial capital investments
  - 3.2.2.2 Issues related to extractables and leachables
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Gap analysis
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Upstream products
- 5.2.1 Bioreactors/fermenters
- 5.2.2 Bioprocess analyzers
- 5.2.3 Process monitoring systems
- 5.2.4 Other upstream products
5.3 Downstream products
- 5.3.1 Filtration & separation
- 5.3.2 Chromatography
- 5.3.3 Consumables & accessories
- 5.3.4 Other downstream products

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Recombinant proteins
6.3 Antibiotics
6.4 Probiotics
6.5 Other applications

Chapter 7 Market Estimates and Forecast, By End User, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Biopharmaceutical companies
7.3 Contract research organizations
7.4 Academic research institutes
7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa